Search results
Showing 2086 to 2100 of 2106 results for technology appraisal
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
More than 1,000 people each year will benefit from NICE's recommendation.
NICE collaborates with international partner agencies to streamline the confidential marking process
NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
How my experience as a patient helped shape NICE guidelines for colorectal cancer
Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future.
NICE recommends a weekly injection for treating growth failure in children
This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.
NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.
More people could be treated out of hospital in the NHS's new respiratory hubs and virtual wards
Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16
In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.
NICE approves groundbreaking one-off gene therapy for severe sickle cell disease
People in England with severe sickle cell disease will be among the first to receive treatment using revolutionary CRISPR gene editing technology, following publication of our final draft guidance today.
KardiaMobile recommended for people having antipsychotic medication
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone-linked ECG device
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.